Studio in aperto, multicentrico, randomizzato, di Fase III mirato a confrontare Topotecan per via orale e Docetaxel per via endovenosa in pazienti con carcinoma polmonare non-microcitoma pretrattato avanzato (Studio IIIB/IV)

Starting date
February 1, 2002
Duration (months)
30
Departments
Medicine
Managers or local contacts
Cetto Gianluigi

Sponsors:

GlaxoSmithKline S.p.A.
Funds: assigned and managed by the department

Project participants

Gianluigi Cetto
Teaching Assistant

Activities

Research facilities